Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...

With a stock price of $3.32, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 10 Unrivaled Penny Stocks to Buy Now.

Earlier this week, Recursion Pharmaceuticals reported that its AI-driven Recursion OS identified 25 drug targets simultaneously and helped cut clinical trial enrollment times by up to half, ...

It can take about 10 years (plus or minus a few) for a brand-new clinical compound to go from the early stages of discovery to the market, and those are just the ones that make it that far. Many are ...

The average one-year price target for Recursion Pharmaceuticals (NasdaqGS:RXRX) has been revised to $6.12 / share. This is a decrease of 10.64% from the prior estimate of $6.85 dated April 25, 2026.

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...

Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a ...

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...